Publications by authors named "Steve Hinton"
Cancers (Basel)
March 2021
Article Synopsis
- CD200/CD200R is an immune checkpoint with potential as a target in lung cancer therapy, showing varied expression in tumor types.
- In a study of 455 lung cancer patients, CD200 was found in 29.7% of non-small cell lung cancer (NSCLC) cases and 33.3% of large cell neuroendocrine carcinoma (LCNEC) patients, with intratumoral variability.
- CD200R was primarily expressed in immune cells, particularly in patients with squamous differentiation, but neither CD200 nor CD200R were linked to survival outcomes, although there was a moderate correlation with PD-L1 levels.
View Article and Find Full Text PDF